Evidence map›Paper›PMID 30142958›Full record

ReviewGenes2018

Profiling DNA Methylation Based on Next-Generation Sequencing Approaches: New Insights and Clinical Applications.

Daniela Barros-Silva, C Joana Marques, Rui Henrique, Carmen Jerónimo

Abstract readReview
In one paragraph

Review in Genes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Antibiotic resistance inFrontiers in microbiology · 2026
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Review
  18. DNA methylation and prediction of biological age.Frontiers in molecular biosciences · 2025
    Review
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Daniela Barros-SilvaCancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua António Bernardino Almeida, 4200-072 Porto, Portugal. daniela.barros.silva94@gmail.com.ORCID 0000-0001-6746-6807
C Joana MarquesGenetics, Department of Pathology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. cmarques@med.up.pt.ORCID 0000-0002-5658-3773
Rui HenriqueCancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua António Bernardino Almeida, 4200-072 Porto, Portugal. rmhenrique@icbas.up.pt.ORCID 0000-0003-3171-4666
Carmen JerónimoCancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua António Bernardino Almeida, 4200-072 Porto, Portugal. carmenjeronimo@ipoporto.min-saude.pt.ORCID 0000-0003-4186-5345

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA methylation is an epigenetic modification that plays a pivotal role in regulating gene expression and, consequently, influences a wide variety of biological processes and diseases. The advances in next-generation sequencing technologies allow for genome-wide profiling of methyl marks both at a single-nucleotide and at a single-cell resolution. These profiling approaches vary in many aspects, such as DNA input, resolution, coverage, and bioinformatics analysis. Thus, the selection of the most feasible method according with the project's purpose requires in-depth knowledge of those techniques. Currently, high-throughput sequencing techniques are intensively used in epigenomics profiling, which ultimately aims to find novel biomarkers for detection, diagnosis prognosis, and prediction of response to therapy, as well as to discover new targets for personalized treatments. Here, we present, in brief, a portrayal of next-generation sequencing methodologies' evolution for profiling DNA methylation, highlighting its potential for translational medicine and presenting significant findings in several diseases.

Indexed as

DNA methylationepigenomicsnext-generation sequencingsingle-cell resolution

Identifiers

PMID30142958
PMCPMC6162482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.